AVBP · NASDAQ · Biotechnology

ArriVent BioPharma (AVBP)

Develops licensed oncology assets led by firmonertinib and antibody-drug conjugates.

$30.32
After hours−0.03 (−0.10%)
At close$30.35(+2.05%)